NewslettersMammary Cell NewsNovartis Retreats from TIGIT, Handing $300M Candidate Back to BeiGeneBy Noshin Noorjahan - July 13, 20230272Having paid $300 million to enter the TIGIT space by acquiring ociperlimab in 2021, Novartis is now handing the candidate back to BeiGene.[Fierce Biotech]Press Release